Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 11, 2012, Pages 966-973

  Bragt, M C E ^a,b   Mensink, R P ^a,b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fibrate; Fish oil; Inflammation; Lipids; Lipoprotein particle size; N 3 Long chain polyunsaturated fatty acids; Obesity; Peroxisome proliferator activated receptor

Indexed keywords

BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN; DOCOSAHEXAENOIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FENOFIBRATE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; E-SELECTIN; FATTY ACIDS, OMEGA-3; FEMALE; FENOFIBRATE; FISH OILS; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PPAR ALPHA; RISK FACTORS; TRIGLYCERIDES;

EID: 84868343354     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.12.010     Document Type: Article

References (32)

1. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11:779-791.
2. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
3. Delerive P., Fruchart J., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459.
4. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65:1645S-1654S.
5. Stalenhoef A.F., de Graaf J., Wittekoek M.E., Bredie S.J., Demacker P.N., Kastelein J.J. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 2000, 153:129-138.
6. Plat J., Mensink R.P. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000, 148:101-112.
7. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
8. Wopereis S., Rubingh C.M., van Erk M.J., Verheij E.R., van Vliet T., Cnubben N.H., et al. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. PLoS ONE 2009, 4:e4525.
9. Bouma M., Laan M., Deneter M., Buurman W. Analysis of soluble adhesion molecules. Immunohistochemistry: a practical approach 1997, 181-196. Oxford University Press, Oxford. A. Johnstone, M. Turner (Eds.).
10. Hiukka A., Westerbacka J., Leinonen E.S., Watanabe H., Wiklund O., Hulten L.M., et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:2190-2197.
11. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagne C., Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 2008, 57:380-386.
12. Ryan K.E., McCance D.R., Powell L., McMahon R., Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007, 194:e123-e130.
13. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138:S419-S420.
14. Chan D.C., Watts G.F., Barrett P.H., Beilin L.J., Mori T.A. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002, 48:877-883.
15. Madsen T., Christensen J.H., Blom M., Schmidt E.B. The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Br J Nutr 2003, 89:517-522.
16. Yusof H.M., Miles E.A., Calder P. Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 2008, 78:219-228.
17. Jellema A., Plat J., Mensink R.P. Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J Clin Invest 2004, 34:766-773.
18. Plat J., Jellema A., Ramakers J., Mensink R.P. Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. J Nutr 2007, 137:2635-2640.
19. Pot G.K., Brouwer I.A., Enneman A., Rijkers G.T., Kampman E., Geelen A. No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr 2009, 83:1353-1359.
20. Grundy S.M., Vega G.L. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987, 83:9-20.
21. Forcheron F., Cachefo A., Thevenon S., Pinteur C., Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51:3486-3491.
22. Harris W.S., Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol 2006, 17:387-393.
23. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001, 88:24N-29N.
24. Hossain M.A., Tsujita M., Gonzalez F.J., Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 2008, 51:258-266.
25. Despres J.P., Lemieux I., Salomon H., Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 2002, 251:490-499.
26. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006.
27. Minihane AM. Fatty acid-genotype interactions and cardiovascular risk. Prostaglandins Leukot Essent Fatty Acids;82:259-64.
28. Deckelbaum R.J., Granot E., Oschry Y., Rose L., Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 1984, 4:225-231.
29. Fasching P., Rohac M., Liener K., Schneider B., Nowotny P., Waldhausl W. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study. Horm Metab Res 1996, 28:230-236.
30. Otto C., Ritter M.M., Soennichsen A.C., Schwandt P., Richter W.O. Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. Metabolism 1996, 45:1305-1311.
31. Mozaffarian D. Fish, n-3 fatty acids, and cardiovascular haemodynamics. J Cardiovasc Med (Hagerstown) 2007, 1(Suppl. 8):S23-S26.
32. Richard D., Bausero P., Schneider C., Visioli F. Polyunsaturated fatty acids and cardiovascular disease. Cell Mol Life Sci 2009, 66:3277-3288.